[Questions and answers about bisphosphonates].
Letonturier
Philippe
P
D000284:Administration, Oral; D000367:Age Factors; D019386:Alendronate / Q000008:administration & dosage / Q000627:therapeutic use; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001851:Bone Diseases, Metabolic / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006934:Hypercalcemia / Q000517:prevention & control; D008297:Male; D008336:Mandibular Diseases / Q000139:chemically induced; D008439:Maxillary Diseases / Q000139:chemically induced; D008875:Middle Aged; D010001:Osteitis Deformans / Q000188:drug therapy; D010014:Osteolysis / Q000188:drug therapy; D010020:Osteonecrosis / Q000139:chemically induced; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy; D012307:Risk Factors; D016103:Spinal Fractures / Q000517:prevention & control; D013997:Time Factors
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D019386:Alendronate